MarketScreener Editorial Features Zealand Pharma A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-04 am EDT			5-day change	1st Jan Change
326.30 ^DKK	+9.02%		+0.43%	-30.04%

Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
Jun. 05	Zealand Pharma A/S Presents Additional Data From Phase 2 ZUPREME-1 Trial Evaluating Petrelintide At The American Diabetes Association 2026 Scientific Sessions	CI

	Zealand Pharma suspends obesity project to focus on programs with greater potential	November 13, 2025 at 10:33 am EST
	Zealand Pharma, a new competitor for Novo Nordisk?	January 24, 2024 at 10:14 am EST